Effects of 5-aminolevulinic acid on cognitive functions in normal subjects using fMRI

Effects of 5-aminolevulinic acid on cognitive functions in normal subjects using fMRI - Effects of 5-aminolevulinic acid on cognitive functions in normal subjects using fMRI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009355

Enrollment

Registered

2012-11-18

Start date

2012-11-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adults

Interventions

1day 1 time 5-aminolevulinic acid 50mg washout duration 1 week 1day 1 time placebo 1day 1 time placebo washout duration 1 week 1day 1 time 5-aminolevulinic acid 50mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy adults. Subjects with no history of psychiatric disorders.

Exclusion criteria

Exclusion criteria: Subject with history of porphyria, hemochromatosis or viral hepatitis. Subject with serious disease such as renal, hepatic or cardiac disease. Subject with photosensitivity. Subject taking drug within 2 weeks of the trial. Subject with contraindications to MRI.

Design outcomes

Primary

Measure	Time frame
Comparison of BOLD signal changes measured by fMRI between placebo and 5-aminolevulinic acid conditions.	—

Countries

Japan

Contacts

Public ContactYumiko Ikeda

Nippon Medical School, Graduate School of Medicine Department of Pharmacology

y-ikeda@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026